Tomasz Klupa, Poland

Jagiellonian University Medical College Department of Metabolic Diseases

Presenter of 1 Presentation

SWITCHING FROM NPH INSULIN TO GLARGNIE U300 RESULTS IN SIGNIFICANT DECREASE OF HBA1C AND REDUCTION OF HYPOGLYCEMIA RISK – RESULTS OF MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY

Session Name
NEW INSULIN ANALOGUES
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:33 - 09:34

Abstract

Background and Aims

The aim of this study was to evaluate the efficacy and safety of glargine U300 in patients with type 2 diabetes (DM2) recently switched from NPH insulin in real-life settings

Methods

We conducted a national, observational, multicenter, prospective, 24-weeks product registry. The primary endpoint was percentage of patients reaching HbA1c reduction of 0.5% or more at the end of the study (EOS); the secondary endpoints were: FPG and HbA1c level at EOS and change from baseline, number of of participants, who experienced ≥1 episode of symptomatic nocturnal hypoglycemia.

Results

Among 469 analyzed patients, the primary endpoint was achieved by 71.7% of patients. HbA1c decreased by 1.02 ± 1.11 % (p<0.0000 vs. baseline) from 9.19 ± 1.11 % at baseline to 8.17 ± 1.17 % at EOS. Average FPG decreased by 37.1 ± 44.5 mg/dL (p<0.0000 vs. baseline) from 178.0 ± 46.0 mg/dL to 140.9 ± 40.7 mg/dL at EOS. The number of participants, who experienced ≥1 episode of symptomatic nocturnal hypoglycemia decreased significantly from 76 (66.1%) at baseline to 9 (14.8%) after 24 weeks of observation (p<0.0000). Average annual rate of symptomatic nocturnal hypoglycemia episodes was 0.33. None of the patients had severe hypoglycemia after switching to glargine U300 throughout whole observation period. The body weight did not change significantly.

Conclusions

It has been shown that people with uncontrolled T2D treated with NPH that switching to Gla-300 significantly improved their glycemic control while significantly decreasing the number of both symptomatic and nocturnal hypoglycemia events

Hide